血清CXCL10在131I治疗Graves病中的测定意义
Significance of Determination of the Changes in Serum Level of CXCL10 in Patients with Graves' Disease After Radioactive Iodine Therapy
李卫鹏 1申勇 1胡永全 1孙伟莉 1袁媛 1袁超1
作者信息
- 1. 安徽蚌埠医学院第一附属医院核医学科,233004
- 折叠
摘要
目的:旨在探讨CXCL10的检测在放射性碘治疗Graves病中的临床应用价值.方法:ELISA分别测定初诊的甲亢患者以及甲亢患者131I治愈后的血清CXCL10的水平,并与正常对照组比较,随后作统计分析CXCL10水平与FT3、FT4是否存在一定的相关性.结果:甲亢患者的CXCL10水平显著高于正常对照组,在131I治愈后的血清水平显著下降,降至正常水平;CXCL10水平与FT3、FT4浓度呈正相关.结论:CXCL10水平与甲状腺的功能密切相关,可作为评判甲亢患者131I治疗效果的有价值的指标.
Abstract
Objective To investigate the significance of determination of the changes in serum level of CXCL10 in the patients with Graves' disease after radioactive iodine ( 131 I) therapy. Methods Level of serum CXCL10 in the patients with Graves' disease, the cured patients treated with 131I and compared to the normal control group. Serum CXCL10 level was measured by ELISA. The relationship among CXCL10, free triiodothyronine (FT3) and free thyroxine (FT4) ,then made an analysis statistically. Results The level of CXCL10 in patients with Graves' disease expressed significantly higher than that in the nonnal control (P <0.05) , meanwhile, CXCL10 in the cured patients decreased significantly (P <0. 05) ; and CXCL10 was positively correlated with FT3 and FT4 (P < 0.05). Conclusion The level of CXCL10 was correlated with function of thyroid, CXCL10 might be a valuable indicant to evaluate the therapeutic efficay of Graves' disease after 131I treatment .
关键词
r干扰素诱导蛋白(CXCL10,IP-10)/放射性碘/Graves病/游离三碘甲状腺原氨酸/游离甲状腺素Key words
CXCL10/radioactive iodine/Graves' disease/FT3/FT4引用本文复制引用
基金项目
安徽省高等学校省级自然科学研究项目(KJ2009B217Z)
出版年
2013
NETL
NSTL
维普
万方数据